StockNews.com Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Buy

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.

Several other research analysts have also issued reports on ALNY. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Wolfe Research started coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Finally, Chardan Capital lowered their target price on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $215.88.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $143.31 on Monday. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $218.88. The stock has a market capitalization of $18.05 billion, a price-to-earnings ratio of -40.26 and a beta of 0.39. The stock has a fifty day moving average of $150.21 and a 200-day moving average of $165.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same quarter in the previous year, the company posted ($1.68) earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals will post -4.46 EPS for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Quent Capital LLC grew its stake in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the period. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $38,000. GAMMA Investing LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $52,000. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $52,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.